Sp736
YOUR AGA PAC: FACT AND FICTION
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved. We will discuss AGA advocacy priorities, a model for removing barriers to high-value care in inflammatory bowel disease and GI, and how to most effectively engage in collaborative advocacy on behalf of the GI community.
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved. We will discuss AGA advocacy priorities, a model for removing barriers to high-value care in inflammatory bowel disease and GI, and how to most effectively engage in collaborative advocacy on behalf of the GI community.
Presenter
Tracks
Related Products
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
PANEL DISCUSSION
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
